Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors

Journal of Medicinal Chemistry

Volumn 48, Issue 23, 2005, Pages 7343-7350

  Brizzi, Antonella ^a   Brizzi, Vittorio ^a   Cascio, Maria Grazia ^b   Bisogno, Tiziana ^b   Sirianni, Rossella ^a   Marzo, Vincenzo Di ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b Endocannabinoid Research Group   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11 (2 HEXYL 5 HYDROXYPHENOXY)UNDECANOIC ACID CYCLOPROPYLAMIDE; 11 (3 HYDROXY 4 HEXYLPHENOXY)UNDECANOIC ACID CYCLOPROPYLAMIDE; 11 (3 HYDROXY 5 PENTYLPHENOXY)UNDECANOIC ACID CYCLOPROPYLAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENYLATE CYCLASE; ANANDAMIDE; ANANDAMIDE MEMBRANE TRANSPORTER; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CARRIER PROTEIN; CYCLIC AMP; DECYLBENZOIC ACID DERIVATIVE; FATTY ACID AMIDASE; FORSKOLIN; HEXYLRESORCINOL; OLIVETOL; PHENOL DERIVATIVE; RADIOLIGAND; RESORCINOL; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CELL STRAIN COS1; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIGAND BINDING; MOUSE; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; RAT; RECEPTOR AFFINITY; SPLEEN; STRUCTURE ACTIVITY RELATION;

AMIDES; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BRAIN; CAPROATES; CELL LINE; CYCLIC AMP; DRUG DESIGN; FATTY ACIDS; LIGANDS; MEMBRANE TRANSPORT PROTEINS; PALMITATES; POLYUNSATURATED ALKAMIDES; RADIOLIGAND ASSAY; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 28544438920     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0501533     Document Type: Article

References (23)

1. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646-1647.
2. Compton, D. R.; Rice, K. C.; De Costa, B. R.; Razdan, R. K.; Melvin, L. S.; Johnson, M. R.; Martin, B. R. Cannabinoid structure-activity relationships: correlation of the receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265, 218-226.
3. Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Howlett, C. A. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34, 605-613.
4. Matsuda, L.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
5. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
6. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
7. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, R. B.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-90.
8. Lee, M.; Yang, K. H.; Kaminski, N. E. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonoyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. 1995, 275, 529-536.
9. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-arachidonoyl-glycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
10. Beltramo, M.; Stella, N.; Calignano, A.; Lin, S. Y.; Makriyannis, A.; Pomelli, D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997, 277, 1094-1097.
11. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384, 83-87.
12. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson, A. J. The terapeutic potential of cannabis. Lancet Neurol. 2003, 2, 291-298.
13. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Curr. Med. Chem. 1999, 6, 721.
14. Childers, S. R.; Sexton, T.; Roy, M. B. Effects of Anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 1994, 47, 711-715.
15. Bonechi, C.; Brizzi, A.; Brizzi, V.; Donati, A.; Francioli, M.; Rossi, C. Conformational Analysis of the N-Arachidonylethanolamide (Anandamide) using Nuclear Magnetic Resonance and Theoretical Calculations. Nuclear Magn. Reson. Chem. 2001, 39, 432-437.
16. (a) Thomas B. F.; Adams I. B.; Mascarella S. W.; Martin B. R.; Razdan R. K. Structure-Activity of Anandamide Analogues: Relationship to a Cannabinoid Pharmacophore. J. Med. Chem. 1996, 39, 471-479.
17. (b) Tong W.; Collantes E. R.; Welsh W. J. Derivation of a Pharmacophore Model for Anandamide Using Constrained Conformational Searching and Comparative Molecular Field Analysis. J. Med. Chem. 1998, 41, 4207-4215.
18. Reggio, P. H.; Traore, H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem. Phys. Lipids 2000, 108 (1-2), 15-35.
19. Di Marzo, V.; Bifulco, M.; De Petroncellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discuss. 2004, 3, 771-784.
20. Crescenza, A.; Botta, M.; Corelli, F.; Santini, A.; Tafi, A. Cyclic dipeptides. 3. Synthesis of methyl (R)-6[(tert-butoxycarbonyl)-amino]-4,5,6,7- tetrahydro-2-methyl-5-oxo-1,4-thiazepine-3-carboxylate and its hexahydro analogues: elaboration of a novel dual ACE/NEP inhibitor. J. Org. Chem. 1999, 64, 3019-3025.
21. Di Marzo, V.; Griffin, G.; De Petrocellis, L.; Brandi, I.; Bisogno, T.; Williams, W.; Grier, M. C.; Kulasegram, S.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 2002, 300, 984-991.
22. Melck, D.; Rueda, D.; Galve-Roperh, I.; De Petrocellis, L.; Guzman, M.; Di Marzo, V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 1999, 463(3), 235-40.
23. Brizzi, A.; Brizzi, V.; Sirianni, R.; Di Marzo, V.; Cascio, M. G.; Bisogno, T. Nuovi potenti ligandi del recettori dei cannabinoidi. It. Pat. RM2005, A000037, 25 January 2005.